Zacks Research Has Negative Estimate for Novavax Q4 Earnings

Novavax, Inc. (NASDAQ:NVAX) – Equities research analysts at Zacks Research reduced their Q4 2026 earnings per share (EPS) estimates for Novavax in a report issued on Wednesday, February 26th. Zacks Research analyst S. Ganoria now forecasts that the biopharmaceutical company will earn $0.40 per share for the quarter, down from their previous forecast of $0.45. The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.24. The business had revenue of $88.31 million during the quarter, compared to analysts’ expectations of $85.48 million. During the same quarter in the previous year, the business posted ($1.44) EPS.

NVAX has been the subject of a number of other research reports. BTIG Research assumed coverage on Novavax in a research note on Friday. They issued a “buy” rating and a $19.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Novavax in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $18.00.

Novavax Trading Down 3.6 %

NASDAQ:NVAX opened at $7.06 on Friday. Novavax has a twelve month low of $3.81 and a twelve month high of $23.86. The firm has a market capitalization of $1.13 billion, a price-to-earnings ratio of -3.12, a PEG ratio of 2.85 and a beta of 2.14. The firm’s fifty day simple moving average is $8.52 and its 200 day simple moving average is $10.00.

Insider Buying and Selling at Novavax

In other Novavax news, Director James F. Young sold 5,400 shares of the firm’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total transaction of $43,200.00. Following the completion of the transaction, the director now directly owns 51,760 shares of the company’s stock, valued at $414,080. This trade represents a 9.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Rachel K. King sold 4,150 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $9.02, for a total transaction of $37,433.00. Following the transaction, the director now directly owns 14,770 shares in the company, valued at $133,225.40. The trade was a 21.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 14,150 shares of company stock valued at $119,641 in the last three months. Corporate insiders own 1.00% of the company’s stock.

Hedge Funds Weigh In On Novavax

Large investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in shares of Novavax during the fourth quarter worth $27,000. Spire Wealth Management acquired a new stake in Novavax during the fourth quarter worth about $29,000. New Age Alpha Advisors LLC bought a new position in Novavax in the fourth quarter worth about $35,000. KBC Group NV boosted its stake in Novavax by 97.0% in the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock valued at $64,000 after acquiring an additional 3,917 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Novavax by 38.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 1,598 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.